Published in Diabetes Week, February 20th, 2006
According to the company, Exubera is the first noninjectable, inhalable form of insulin to be approved since the discovery of insulin in the 1920s, and represents a major advance in diabetes treatment.
According to the World Health Organization, diabetes has reached epidemic proportions and affects approximately 48 million people in Europe alone. People with diabetes often suffer from debilitating complications due to uncontrolled blood sugar levels including heart disease, amputation, blindness, and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.